Literature DB >> 16398218

Preoperative chemotherapy with irinotecan and mitomycin for FIGO stage IIIb cervical squamous cell carcinoma: a pilot study.

T Tanaka1, K Kokawa, N Umesaki.   

Abstract

PURPOSE OF INVESTIGATION: Patients with FIGO Stage IIIb cervical cancer show cancer propagation to pelvic side walls from the uterus, and the tumors cannot be completely removed by radical hysterectomy. Here, we examined the effects of preoperative irinotecan HCl (CPT-11)-combined chemotherapy on patients with unresectable Stage IIIb cervical squamous cell carcinoma.
METHODS: Eleven patients agreed to participate in the pilot study and received preoperative chemotherapy.
RESULTS: Cervical tumors of all 11 patients showed partial responses in tumor reduction, and radical hysterectomy was successfully performed in ten patients treated with CPT-11 and mitomycin C (MMC). One patient treated with CPT-11 and cisplatin had a 68% reduction of the primary cervical lesion but could not undergo radical surgery because of retroperitoneal cancer progression during chemotherapy.
CONCLUSION: These results indicate that chemotherapy with CPT-11 and MMC could be a useful preoperative treatment for unresectable Stage IIIb cervical squamous carcinoma.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16398218

Source DB:  PubMed          Journal:  Eur J Gynaecol Oncol        ISSN: 0392-2936            Impact factor:   0.196


  3 in total

1.  Preclinical antitumor activity of a nanoparticulate SN38.

Authors:  Mazin F Al-Kasspooles; Stephen K Williamson; David Henry; Jahna Howell; Fengui Niu; Charles J Decedue; Katherine F Roby
Journal:  Invest New Drugs       Date:  2013-01-09       Impact factor: 3.850

2.  Demethylation restores SN38 sensitivity in cells with acquired resistance to SN38 derived from human cervical squamous cancer cells.

Authors:  Tetsuji Tanaka; Tao Bai; Saori Toujima; Tomoko Utsunomiya; Toshihide Matsuoka; Aya Kobayashi; Madoka Yamamoto; Noriyuki Sasaki; Yuko Tanizaki; Hirotoshi Utsunomiya; Junko Tanaka; Kazunori Yukawa
Journal:  Oncol Rep       Date:  2012-01-11       Impact factor: 3.906

3.  Urinary biomarkers for the diagnosis of cervical cancer by quantitative label-free mass spectrometry analysis.

Authors:  Daranee Chokchaichamnankit; Kamolwan Watcharatanyatip; Pantipa Subhasitanont; Churat Weeraphan; Siriporn Keeratichamroen; Narongrit Sritana; Nuttavut Kantathavorn; Penchatr Diskul-Na-Ayudthaya; Kittirat Saharat; Juthamard Chantaraamporn; Chris Verathamjamras; Natacha Phoolcharoen; Kriangpol Wiriyaukaradecha; Nilubol Monique Paricharttanakul; Wandee Udomchaiprasertkul; Thaniya Sricharunrat; Chirayu Auewarakul; Jisnuson Svasti; Chantragan Srisomsap
Journal:  Oncol Lett       Date:  2019-04-08       Impact factor: 2.967

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.